Comparative Pharmacology
Head-to-head clinical analysis: WAYRILZ versus WEZLANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: WAYRILZ versus WEZLANA.
WAYRILZ vs WEZLANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
WAYRILZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-6 (IL-6), thereby reducing inflammation and immune response.
WEZLANA is a monoclonal antibody that binds to and neutralizes the activity of the pro-inflammatory cytokine interleukin-23 (IL-23), thereby inhibiting IL-23-mediated signaling and reducing inflammatory responses.
WAYRILZ 500 mg orally twice daily without regard to meals.
IV: 500 mg every 12 hours over 60 minutes.
None Documented
None Documented
Terminal elimination half-life is 12 hours, supporting twice-daily dosing in patients with normal renal function.
12 hours (range 10-14 hours); clinically, steady-state is achieved after 2-3 days of dosing.
Renal elimination of unchanged drug accounts for 85% of total clearance; fecal/biliary elimination accounts for 12%, with the remainder via metabolic inactivation.
Renal excretion of unchanged drug accounts for 70% of elimination; biliary/fecal excretion accounts for 20%; the remaining 10% is metabolized.
Category C
Category C
Unknown
Unknown